Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lialda for maintenance of ulcerative colitis remission
NCT00151944Phase 3Completed
- Sponsor
- Takeda
- Start
- Nov 2003
- Primary completion
- Mar 2006
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of Salcrozine in ulcerative colitis (UC) (2 arms), sponsored by Takeda. Primary endpoint: Treatment Emergent Adverse Events at 28 months. Started Nov 2003; status: completed.
02
Drugs
Salcrozine
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT00151944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00151944.